BLASETTI FANTAUZZI, CLAUDIA
 Distribuzione geografica
Continente #
NA - Nord America 1.095
EU - Europa 326
AS - Asia 216
AF - Africa 38
SA - Sud America 10
Totale 1.685
Nazione #
US - Stati Uniti d'America 1.084
SE - Svezia 127
IT - Italia 90
IN - India 68
SG - Singapore 62
CN - Cina 52
TG - Togo 35
FI - Finlandia 27
TR - Turchia 27
DE - Germania 20
UA - Ucraina 13
RO - Romania 12
CA - Canada 11
IE - Irlanda 10
AR - Argentina 9
GB - Regno Unito 8
BE - Belgio 4
BG - Bulgaria 3
GR - Grecia 3
NL - Olanda 3
AT - Austria 2
ES - Italia 2
MY - Malesia 2
NG - Nigeria 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
FR - Francia 1
IL - Israele 1
IR - Iran 1
JP - Giappone 1
PL - Polonia 1
SC - Seychelles 1
TW - Taiwan 1
Totale 1.685
Città #
Fairfield 171
Woodbridge 75
Ashburn 71
Chandler 68
Dearborn 66
Seattle 65
Ann Arbor 59
Houston 56
Cambridge 53
Wilmington 53
Princeton 42
Singapore 37
Lomé 35
Plano 34
Istanbul 27
Millbury 23
Beijing 22
Rome 21
Boston 16
Lawrence 14
San Paolo di Civitate 13
San Diego 12
Dublin 11
Genova 11
Federal 9
Andover 8
Kunming 7
Toronto 7
Cagliari 6
Nanjing 6
New York 6
Norwalk 6
Santa Clara 5
Brussels 4
Hefei 4
Hyderabad 4
Mannheim 4
Ottawa 4
Palermo 4
Phoenix 4
Boardman 3
Bremen 3
Falls Church 3
Grafing 3
Sofia 3
Zhengzhou 3
Abuja 2
Bühl 2
Catania 2
Falkenstein 2
Jacksonville 2
Kuala Lumpur 2
London 2
Lugones 2
Noto 2
Redwood City 2
Vienna 2
Xian 2
Americana 1
Block 1
Colle Brianza 1
Cormeilles-en-Parisis 1
Denver 1
Dubai 1
Edinburgh 1
Ferrara 1
Genoa 1
Helsinki 1
Jönköping 1
Leawood 1
Los Angeles 1
Milan 1
Modena 1
Nanchang 1
Nanning 1
Naples 1
Narashino 1
New Delhi 1
Polska 1
Prineville 1
Redmond 1
San Mateo 1
Southend 1
Taipei 1
Trumbull 1
Turin 1
Wenzhou 1
Ürümqi 1
Totale 1.215
Nome #
D-carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation 93
Galectin-3 is essential for proper bone cell differentiation and activity, bone remodeling and biomechanical competence in mice 88
The advanced glycation endproduct Nε-carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention 88
FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice 83
Galectin-3 ablation protects mice from diet-induced NASH. A major scavenging role for galectin-3 in liver 82
Deficiency of the purinergic receptor 2X7 attenuates nonalcoholic steatohepatitis induced by high-fat diet. possible role of the NLRP3 Inflammasome 80
Attivazione del sistema prorenina/renina nella nefropatia diabetica sperimentale 79
Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester. effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice 73
The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis 73
L-carnosine and its derivatives as new therapeutic agents for the prevention and treatment of vascular complications of diabetes 73
Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis 70
Galectin-3 in diabetic patients 68
Metabolically healthy versus metabolically unhealthy obesity 67
La D-carnosina previene la nefropatia diabetica nel topo db/db. 65
Role of galectin-3 in bone cell differentiation, bone pathophysiology and vascular osteogenesis 64
The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: Possible role of NLRP3 inflammasome activation 57
Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis 56
La D-carnosina attenua lo sviluppo di aterosclerosi e malattia renale nel topo ApoE null a dieta grassa. 53
Activation of the prorenin/renin system in experimental diabetic nephropathy 41
L’ablazione del recettore purinergico p2x7 attenua il danno renale indotto dalla dieta grassa iducendo l'attivazione dell'inflammasoma NLRP3. 40
D-carnosine prevents diabetic nephropathy in db/db mice 39
D-carnosine prevents diabetic nephropathy in db/db mice 38
Diabetes and pancreatic cancer: role of advanced glycation endproducts (AGEs) in tumor progression via RAGE activation 38
Effetto dell'alto glucosio su espressione e processamento del recettore della (pro)renina in cellule mesangiali 35
Il deficit del recettore P2X7 attenua la steato-epatite non alcolica (NASH) indotta dalla dieta grassa: possibile ruolo dell’inflammasoma NLRP3 30
La diade galectina-3/rage regola la calcificazione vascolare 25
Espressione e localizzazione di galectina-3 in placche carotidee umane: possibile ruolo nel processo osteogenico aterosclerotico. 25
Il trattamento con octyl-D-carnosina protegge dall’aterosclerosi e dal danno renale indotto dal diabete: evidenze a favore di un ruolo degli AGE nel fenomeno del “legacy effect” 24
Protection from diabetes-induced atherosclerosis and renal disease by Octyl-D-carnosine: evidences for a role of AGEs in hyperclycaemic memory 22
Ruolo di galectina-3 nel rimodellamento osseo: possibili relazioni tra fenotipo scheletrico e metabolismo glucidico 21
P2X(7) deficiency attenuates renal disease induced by high-fat diet 21
Octyl-D-carnosine attenuates atherosclerosis and renal disease in ApoE null mice fed a western diet. 21
P2X7 deficiency attenuates renal disease induced by high-fat diet 21
Role of purinergic receptor 2X7 in renal disease and non-alcoholic steatohepatitis (NASH) associated with metabolic disorders through activation of the NLRP3 inflammasome 20
L’ablazione del recettore P2X7 protegge dalla steato-epatite non alcolica (NASH) indotta da dieta grassa 20
Totale 1.793
Categoria #
all - tutte 4.930
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.930


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020332 0 0 0 15 33 90 61 40 35 22 17 19
2020/2021197 10 14 1 12 2 0 16 45 22 59 14 2
2021/2022299 2 16 17 23 46 7 5 29 35 22 21 76
2022/2023370 84 96 13 28 34 29 7 29 23 3 12 12
2023/2024164 12 34 4 19 16 9 4 18 3 17 6 22
2024/202548 4 7 37 0 0 0 0 0 0 0 0 0
Totale 1.793